Abstract:Herein we report attempts to optimize the pharmacological properties of 5-(2-hydroxyethoxy)-N-acetyltryptamine (5-HEAT), a melatonin receptor ligand previously described by us. Several 5-substituted and 2,5-disubstituted N-acyltryptamines were synthesized and evaluated in vitro for the human cloned MT(1) and MT(2) receptors. From this series of N-acyltryptamines the 2-bromo derivative (5 c) retains the interesting efficacy profile of 5-HEAT and shows increased melatonin receptor affinities; it represents one o… Show more
“…Several 5substituted and 2,5-disubstituted N-acyltryptamines were synthesized for this purpose. 1055 From this series of Nacyltryptamines, the 2-bromo derivative retains an interesting efficacy profile. For this experiment they used PTAB for the bromination of various substrates.…”
Section: -Bromo-55-dimethylhydantoinmentioning
confidence: 99%
“…Spadoni et al reported attempts to optimize the pharmacological properties of 5-(2-hydroxyethoxy)- N -acetyltryptamine, a melatonin receptor ligand. Several 5-substituted and 2,5-disubstituted N -acyltryptamines were synthesized for this purpose . From this series of N -acyltryptamines, the 2-bromo derivative retains an interesting efficacy profile.…”
Bromination is one of the most important transformations in organic synthesis and can be carried out using bromine and many other bromo compounds. Use of molecular bromine in organic synthesis is well-known. However, due to the hazardous nature of bromine, enormous growth has been witnessed in the past several decades for the development of solid bromine carriers. This review outlines the use of bromine and different bromo-organic compounds in organic synthesis. The applications of bromine, a total of 107 bromo-organic compounds, 11 other brominating agents, and a few natural bromine sources were incorporated. The scope of these reagents for various organic transformations such as bromination, cohalogenation, oxidation, cyclization, ring-opening reactions, substitution, rearrangement, hydrolysis, catalysis, etc. has been described briefly to highlight important aspects of the bromo-organic compounds in organic synthesis.
“…Several 5substituted and 2,5-disubstituted N-acyltryptamines were synthesized for this purpose. 1055 From this series of Nacyltryptamines, the 2-bromo derivative retains an interesting efficacy profile. For this experiment they used PTAB for the bromination of various substrates.…”
Section: -Bromo-55-dimethylhydantoinmentioning
confidence: 99%
“…Spadoni et al reported attempts to optimize the pharmacological properties of 5-(2-hydroxyethoxy)- N -acetyltryptamine, a melatonin receptor ligand. Several 5-substituted and 2,5-disubstituted N -acyltryptamines were synthesized for this purpose . From this series of N -acyltryptamines, the 2-bromo derivative retains an interesting efficacy profile.…”
Bromination is one of the most important transformations in organic synthesis and can be carried out using bromine and many other bromo compounds. Use of molecular bromine in organic synthesis is well-known. However, due to the hazardous nature of bromine, enormous growth has been witnessed in the past several decades for the development of solid bromine carriers. This review outlines the use of bromine and different bromo-organic compounds in organic synthesis. The applications of bromine, a total of 107 bromo-organic compounds, 11 other brominating agents, and a few natural bromine sources were incorporated. The scope of these reagents for various organic transformations such as bromination, cohalogenation, oxidation, cyclization, ring-opening reactions, substitution, rearrangement, hydrolysis, catalysis, etc. has been described briefly to highlight important aspects of the bromo-organic compounds in organic synthesis.
“…Compounds with subnanomolar affinity and modest selectivity for the MT 1 subtype (MT 2 /MT 1 selectivity ratios approximately ranging from 20 to 40) have been obtained when a 4‐phenylbutyl group was introduced at the C2‐position of the bicyclic scaffold, as exemplified by compounds 29 [117], 30 [118] and 31 [119] in Figure 3. By replacement of the methoxy group of MLT with a 5‐hydroxyethoxy substituent interesting compounds were obtained, some of which ( 32 [120], 33 [121]) have similar binding affinity for the two receptor subtypes, but functional selectivity on GTPγS binding, as they displayed MT 1 agonist and MT 2 antagonist properties. Taken together, all these results have led to the hypothesis that MT 1 selectivity is favored by replacement of the 5‐methoxy group by a larger substituent.…”
The circadian nature of melatonin (MLT) secretion, coupled with the localization of MLT receptors to the suprachiasmatic nucleus, has led to numerous studies of the role of MLT in modulation of the sleep-wake cycle and circadian rhythms in humans. Although much more needs to be understood about the various functions exerted by MLT and its mechanisms of action, three therapeutic agents (ramelteon, prolonged-release MLT, and agomelatine) are already in use, and MLT receptor agonists are now appearing as new promising treatment options for sleep and circadian-rhythm related disorders. In this review, emphasis has been placed on medicinal chemistry strategies leading to MLT receptor agonists, and on the evidence supporting therapeutic efficacy of compounds undergoing clinical evaluation. A wide range of clinical trials demonstrated that ramelteon, prolonged-release MLT and tasimelteon have sleep-promoting effects, providing an important treatment option for insomnia and transient insomnia, even if the improvements of sleep maintenance appear moderate. Well-documented effects of agomelatine suggest that this MLT agonist offers an attractive alternative for the treatment of depression, combining efficacy with a favorable side effect profile. Despite a large number of high affinity nonselective MLT receptor agonists, only limited data on MT₁ or MT₂ subtype-selective compounds are available up to now. Administration of the MT₂-selective agonist IIK7 to rats has proved to decrease NREM sleep onset latency, suggesting that MT₂ receptor subtype is involved in the acute sleep-promoting action of MLT; rigorous clinical studies are needed to demonstrate this hypothesis. Further clinical candidates based on selective activation of MT₁ or MT₂ receptors are expected in coming years.
“…In order to minimize the number of reaction steps and to achieve the best possible overall yield, we have chosen a one-pot Ra-Ni hydrogenation/acetylation procedure previously reported for the reduction of nitriles to give directly the N-acetylated product. 11 We were pleased to find that aldoxime 8 could be converted into agomelatine using Ra-Ni hydrogenation in the presence of acetic anhydride in an excellent 98% yield.…”
Section: Figure 1 Chemical Structures Of Melatonin and Agomelatinementioning
Agomelatine was synthesized from (2-methoxynaphthalene-8-yl)oxoacetic acid in a four-step approach involving borane reduction, semipinacol rearrangement of the resulting diol, aldoxime formation, and Ra-Ni hydrogenation/acetylation in 51% overall yield. The reaction sequence includes a novel one-pot conversion of an aldoxime into an N-acetylamine. The synthetic route could be useful as a new approach towards N-acetylarylethylamines.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.